US clinical-stage pharma Keros Therapeutics (Nasdaq: KROS) today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase II clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH), including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events.
Keros shares slumped 17.4% to $10.31 by late morning trading on the development.
On December 12, 2024, the company announced that it had voluntarily halted the 3.0 mg/kg and 4.5 mg/kg treatment based on the observation of pericardial effusions at those dose levels. That news caused a 73% slump in its share price.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze